Isala Klinieken Stichting — Clinical Trial Site

158 Registered trials

80 Currently recruiting

Organisation

Isala Klinieken Stichting

Location

Zwolle, Netherlands

Identifier

ORG-100021668

Address

Reggersweg 2, 7943 KC, Netherlands

Departments

#2202: oncology
#3726: Cardiology
031002: Pediatrics
2606:Cardiology
5003; Oncology
Afd. Interne geneeskunde
Afdeling Longgeneeskunde
Anesthesiology
Cardiology
Cardiology research
Clinical Pharmacy
Department of abdominal surgery
Department of Internal Medicines
Department of Pulmonology
Department of Radiothearpy
Dept of Medical Oncology
Dept of Oncology
Emergency Department
Gynecology and obstetrics
Hematolgoie
hematologie, oncologie
Hematology
IC Neonatology
Intensive Care
Internal Medicine
Internal Medicine - Nephrology
Internal Oncology
interne geneeskunde
Interne onc
Isala Oncology Center
Kindergeneeskunde
Longgeneeskunde
Longziekten
Lung department
Lung Diseases
Medical Oncology
Medische Oncologie
N/A
Neonatology
Nephrology
Neurologie
Neurology
NLD003:Polyclinic - Pulmonary Diseases
Obstetrics & Gynecology
Oncologie
Oncologisch Centrum
Oncology
Oncology center
Orthopedic surgery
Paediatric Gastroenterology
Pediatrics
Pneumology
Poli Longgeneeskunde
Poli Longziekten
Poli Longziekten V2.2
Pulmonary medicine
Pulmonary Science
Pulmonology
Radiology, Oncology
Radiotherapy
Reproductive medicine and gynecology
Research Department Cardiology
Research facultly
Research oncology centrum
Reumatologie
Sports Medicine
Stichting Isala Klinieken
Surgery
Urology
V2.2 poli longziekten
Vasculair geneeskundige
Verloskunde & Gynaecologie

Clinical trials at this site (158)

Search interface

SAFEST Not authorised

2022-502059-79-00 Ischemic stroke or transient ischemic attack 6
RATE: Reduced anticoagulation targets in extracorporeal life support Pending

2023-509675-16-01 All patients who receive ECMO treatment during the stud 5
Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study Pending

2024-510617-15-00 Non-metastatic resectable pancreatic cancer 5
Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases in patients with a low clinical risk sco… Pending

2024-512850-10-00 Resectable colorectal rectal metastases without extrahe 5
Avelumab Short Maintenance Trial Pending

2024-512975-11-01 urothelial cancer 11
Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial) Pending

2024-516718-39-00 Melanoma 6
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer Pending

2025-522883-34-00 Metastatic cervical cancer 6
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5
AchilleS tendinoPathy treated with cortIcosteRoid injEctions. Pending

2025-524057-13-00 Achilles tendinopathy 5
Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Triple negative breast cancer 5
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043) Recruiting

2025-524160-38-00 Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI- 5 2026-05-12
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting

2025-523104-71-00 Obesity or Overweight Without Type 2 Diabetes 5 2026-05-08
A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting

2025-522767-15-00 Acute Myeloid Leukemia 5 2026-01-27
Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting

2024-520433-76-00 Newly Diagnosed Multiple Myeloma 4 2026-01-08
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Safety of ELGN-2112 in Populations… Recruiting

2024-517102-29-00 Intestinal Malabsorption 5 2025-11-19
ASPIRING Recruiting

2024-516188-10-00 Intracerebral haemorrhage 6 2025-10-07
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting

2024-512753-24-00 Acute Myeloid Leukemia (AML) 5 2025-08-05
A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C… Recruiting

2024-517968-36-00 non-small cell lung cancer 5 2025-07-08
A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML… Recruiting

2024-512733-32-00 Acute Myeloid Leukemia (AML) 5 2025-03-31
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal… Recruiting

2023-507097-41-01 Patients with limited-stage small cell lung cancer (LS- 5 2025-03-20
A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision fo… Recruiting

2024-517410-15-01 Rectal cancer 5 2025-01-14
A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI… Recruiting

2024-511404-17-00 Unresectable or metastatic NRAS mutant cutaneous melano 5 2024-10-07